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Abstract 
Many individuals living in remote and resource-limited regions around the world face a barrier to 
adequate medical care due to the unavailability of diagnostic instrumentation to perform standard 
measurements which diagnose disease and inform treatment. Factors which limit the availability of 
diagnostics include both the costs of instrumentation and per-test costs, inadequate portability, the 
requirement for a laboratory facility, the time required to perform the test, and a need for highly-trained 
personnel to operate the instrumentation. While a wide variety of approaches primarily based on 
innovations in micro- and nanotechnology have been reported toward the point-of-care sensing of 
biological entities, none has yet emerged as a comprehensive solution to the fundamental problems of 
diagnostic testing in resource-limited settings. In strides toward a platform for low-cost, rapid, easy-to-use 
point-of-care diagnostics, we present an ELISA-inspired lab-on-a-chip strategy for biological detection 
based on liposome tagging and ion-release impedance spectroscopy. Ion-encapsulating 
dipalmitoylphosphatidylcholine (DPPC) liposomes can be functionalized with antibodies and are stable in 
deionized water yet become permeable for ion release upon heating, making them ideal reporters for 
electrical biosensing of surface-immobilized antigens. We demonstrate the quantification of these 
liposomes by real-time impedance measurements and the detection of HIV, which we have selected as a 
problem to target in the development of this platform, which ultimately can be applied more broadly to 
other biomolecules and antigens. By showing the detection of viruses on this biosensor platform, we have 
demonstrate a proof-of-concept which will be further optimized and advanced toward quantitative 
determination of viral load from whole blood specimens.   
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1. Introduction 
Approximately 34 million people worldwide are living with Human Immunodeficiency Virus (HIV), 
the virus that causes Acquired Immune Deficiency Syndrome (AIDS) [1]. Epidemiological trends reflect 
recent progress in the expansion of access to prevention, testing, counseling and treatment, including a 
drop in new HIV infections from 3.1 million annually in 2002 to 2.7 million in 2010 and a decline in 
AIDS-related deaths from 2.2 million annually in 2006 to 1.8 million in 2010 [1]. 
These data do not mask the epidemic proportions of the disease, however, and combating HIV/AIDS 
remains one of eight Millennium Development Goals outlined by the United Nations for reducing 
extreme poverty [2]. The disease disproportionately affects the world’s poorest nations – for example, 
68% of all people living with HIV reside in Sub-Saharan Africa, a region that represents only 12% of the 
global population [1]. Because of the absence of an effective vaccine, the availability of antiretroviral 
medications and accessibility of testing represent the most significant grand challenges in fighting the 
HIV/AIDS epidemic worldwide. These two challenges do not stand independently, however, as regular 
and appropriate monitoring is required for effective treatment. 
HIV infection is typically diagnosed by serologic tests indicating the presence of anti-HIV antibodies, 
a test for which rapid point-of-care assays are available including tests of oral fluids and whole blood 
from a finger prick [3]. Following diagnosis, guidelines issued by the Infectious Disease Society of 
America (IDSA) recommend immediate evaluation of two core markers of the progress of infection: the 
CD4+ T lymphocyte count and plasma viral load, in addition to antiretroviral therapy (ART) resistance 
testing, a complete blood count, and blood chemistry panels [3]. Typical levels of CD4+ T lymphocytes 
and plasma viral load during the course of HIV infection are depicted in Fig. 1 [4], [5]. World Health 
Organization (WHO) guidelines recommend the initiation of ART for people living with HIV upon 
determination of a CD4 count less than or equal to 350 cells/mm
3
, while CD4 count monitoring is 
recommended to be performed at least every six months for individuals not yet eligible for ART [6]. 
During treatment, the WHO recommends CD4 counting and viral load monitoring in a routine approach 
[6]. Ultimately, the goal of regular monitoring is to guide treatment strategies toward the prevention of 
immunological failure (CD4 count below baseline, 50% of on-treatment peak value, or 100 cells/mm
3
), 
and virological failure (viral load above 5000 copies/ml) [6]. 
The CD4 count reflects the health of the immune system and is occasionally paired with the CD8+ T 
lymphocyte count in assessment of an HIV-positive patient, although there are conflicting reports on the 
utility of CD8 counts or CD4/CD8 ratio [3], [7].  Viral load measurements complement the CD4 count 
and are a direct assessment of viral number. Viral load is typically assessed by quantifying viral RNA in 
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the blood plasma, although alternative approaches to quantifying plasma load as well as intracellular viral 
reservoirs have been described. A review of the HIV lifecycle in Fig. 2 reveals several traditional and 
alternative biomarkers for monitoring virus levels. 
Because of retrovirus integration with the host in the form of a provirus, HIV establishes a long-term 
reservoir and accomplishes production of new virions in host cells – a process which can be interrogated 
at all levels of gene expression inside the cell. Detection of proviral DNA is the most commonly assessed 
intracellular marker and has established clinical relevance as a method for assessing virus status in 
newborns in whom mother-to-child transmission of HIV is suspected, since passive transfer of maternal 
antibodies can produce false-positives on serological tests [3]. However, assessment of levels of cell-
associated unspliced and multiply-spliced HIV RNA have also been suggested as clinical markers of 
disease progression [8–10], to have prognostic value [11], or to be useful metrics for assessing ART 
efficacy [12], [13]. Laboratory-based methods for the detection of cell-associated RNA have been 
demonstrated [14], [15]. 
The core principles of micro- and nanotechnology offer opportunities for new approaches to 
monitoring all of these biomarkers. Modern fabrication techniques have enabled the development of novel 
optical, mechanical and electrical biosensor platforms with greater sensitivity for cell and biomolecule 
sensing, including those which replace or eliminate the need for expensive and bulky components of 
state-of-the-art clinical diagnostic instruments. Microfluidic systems enable precise manipulation of small 
volumes of biological fluids, significantly decreasing blood sample size requirements and allowing for 
less invasive collection techniques. Finally, smaller instrument footprints promise a high degree of 
portability in sample-to-answer systems. 
This review emphasizes approaches toward the implementation of technologies for CD4 T 
lymphocyte counting, plasma viral load and proviral load determination in resource-limited settings. 
Approaches vary from adaptations of state-of-the art technologies to novel assays based on innovations in 
micro- and nanotechnologies. Several technologies discussed here address testing challenges through 
complete sample-to-answer integrated systems while others demonstrate partial solutions, yet demonstrate 
potential for application in an integrated system. 
In addition to the typical requirements for sensitivity and specificity required of diagnostic 
technologies, the criteria for effective CD4 counting or viral load determination in resource-limited 
settings includes: (1) the test must be able to operate at the point-of-care, addressing the need to bring 
testing to patients with limited ability to travel to a healthcare facility, (2) the test must be rapid, 
addressing complications in resource-limited settings associated with healthcare provider follow-up when 
results cannot be obtained same-day, (3) the test must be low-cost, mitigating the financial burden on 
individuals, agencies or governments in poor countries, and (4) the test must be easy to use, allowing for 
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implementation in areas where skilled technicians are not available. The end goal is a comprehensive 
technology capable of taking whole blood input in the form of a finger-prick or heel-prick, and outputting 
the desired results. 
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Figures 
 
 
Fig. 1. Typical course of infection. Typical CD4 counts and plasma viral load during the course of an HIV 
infection. Adapted from [4], [5]. 
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Fig. 2. HIV lifecycle showing critical points for virus detection. Virions in plasma infect CD4+ T 
lymphocytes via the high-affinity interaction between the viral surface protein gp120 and the host cell 
CD4 receptor and CCR5 co-receptor. This docking facilitates fusion of the viral and cell membranes and 
injection the protein capsid into the cytoplasm which dissociates to release viral RNA. Highly error-prone 
reverse transcriptase makes a cDNA copy of the viral genome which is targeted to the host cell nucleus 
and integrated with the host genome by viral protein integrase. Host cell gene expression including 
mRNA alternative splicing ensues, resulting in expression of both viral structural protein precursors and 
those involved in the facilitation of viral gene expression. Genomic RNA and structural proteins are 
targeted to the cell surface where budding occurs. Maturation facilitated by protease action takes place 
after budding. Labels indicate biomarkers for viral diagnostics, including (A) Viral RNA in plasma (B) 
Reverse Transcriptase in plasma (C) Capsid protein p24 in plasma (D) Proviral DNA (E) Cell-associated 
unspliced RNA (F) Cell-associated spliced RNA.
This text originally appeared in Damhorst GL, Watkins NN, Bashir R, "Micro and nanotechnology for 
HIV/AIDS diagnostics in resource-limited settings," IEEE Trans Biomed Eng. 2013 Mar;60(3):715-26. 
doi: 10.1109/TBME.2013.2244894. 
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2. Literature Review 
2.1 Plasma Viral Load 
2.1.1 Current State of the Art 
Several challenges complicate the monitoring of HIV plasma viral load, including the diversity of 
HIV forms and subtypes as the result of high recombination and mutation rates – one of the primary 
barriers to the development of an effective vaccine [16]. Effective viral load devices must therefore be 
capable of flexibility among genetic or antigenic variation from infection to infection. 
State of the art technology for plasma viral load involves amplification and detection of viral nucleic 
acid. Tests approved by the U.S. Food and Drug Administration for quantification of plasma viral load by 
nucleic acid amplification are listed in Table 1 [17–20]. To date, however, no Reverse-Transcription 
Polymerase Chain Reaction (RT-PCR), branched DNA (bDNA), or Nucleic Acid Sequence-Based 
Amplification (NASBA) assay has demonstrated the qualities necessary to become ubiquitous in 
resource-limited settings. 
Multiple studies have also explored the possibility of transporting dried blood or plasma specimens 
from more primitive sites to a capable laboratory as a global health solution for plasma viral load testing, 
though this does not address the ultimate need for a rapid, point-of-care test [21–24]. Progress toward 
viral load in resource-limited settings has emerged in the form of assays for other biomolecular 
components of HIV, including the structural capsid protein p24 and the enzyme reverse transcriptase, 
platforms aimed at the miniaturization of the amplification and/or detection aspects of nucleic acid 
quantification, and isolation of whole viruses from blood samples as a processing step toward direct 
particle counting. Several novel non-quantitative technologies for detection of HIV in plasma have been 
reported, including a recent report from De la Rica and Stevens on a gold-nanoparticle-based p24 assay 
that can be analyzed with the naked eye [25]. Non-quantitative techniques are only presented extensively 
in this section, however, when considered relevant to the development of a future quantitative technique. 
2.1.2 Global Health Solutions 
2.1.2.1 Detection of p24 capsid proteins 
The Enzyme-Linked ImmunoSorbent Assay (ELISA) is a standard technique for laboratory detection 
and quantification of proteins. P24 assays developed by Perkin Elmer Life Sciences (Boston, MA) [26–
29], NEN Life Science Products (Geneva, Switzerland) [30], and Biocentric (Bandol, France) [31] have 
been evaluated for use in resource limited settings but sensitivity [27], reliability [27], [30] and false 
positives [31] have been cited as reasons limiting implementation of these tests in resource-limited 
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settings. Alternative assays have been developed, however, for the detection of p24 as the basis for HIV 
quantification [32–36]. 
Lee, et al. sought to improve upon the standard ELISA with a nanoarray patterned with anti-p24 
antibodies by dip-pen nanolithography [32]. Instead of an enzyme with chemiluminescent product, a gold 
nanoparticle probe functionalized with anti-p24 antibody was used as a secondary tag and detected with 
atomic force microscopy and scanning electron microscopy. While this report serves as an interesting 
proof-of-concept, a more appropriate detection technique is necessary as these microscopy techniques are 
probably not suited for low-cost, portable applications.  
Parpia, et al. described a dipstick assay for p24 designed for rapid detection of HIV in infants [33]. 
Plasma samples were mixed with heat shock buffer, heated to disrupt immune complexes, and then 
exposed to the dipstick test. The sample hydrates an antibody-conjugated tag and flows laterally by 
capillarity to a test line where antigen-bound tags are immobilized. The dipstick is then scanned and 
analyzed by a computer for semi-quantitative results. This technique makes strides toward the ideal 
platform for point-of-care viral load determination, although integrated scanning and analysis may be 
necessary to achieve the desired ease-of-use. 
The concept of a biobarcode detection assay was introduced by Nam, Thaxton and Mirkin in Science 
in 2003 [37]. The technique was later adapted for detection of HIV capsid protein p24 [34–36] and an 
overview of the concept is depicted in Fig. 3 [34]. The biobarcode assay is a modification of traditional 
ELISA techniques in which p24 is first captured in microtiter wells coated with anti-p24 antibody and 
subsequently tagged with a biotinylated anti-p24 [34]. Streptavidin-coated gold nanoparticles are then 
bound to the secondary antibody, providing a substrate for attachment of biotinylated barcode DNA. 
Following washing and heating, biobarcode DNA immobilized on gold nanoparticles bound to p24-
antibody sandwiches is eluted and hybridized to a sequence complementary to half of the barcode DNA 
on a glass slide. A DNA-probe labeled gold nanoparticle binds to the other half of the immobilized 
barcode DNA and silver ions are reduced by hydroquinone on the surface, amplifying the visualization of 
biobarcode signals. A later version of this assay replaced the microtiter wells with antibody-coated 
magnetic nanoparticles which facilitated the separation of the antigen-nanoparticle complexes from 
solution [36]. This biobacode technique has demonstrated promising strides toward the grand challenge of 
early HIV detection [35] and bears the potential for a quantitative test, yet it has not yet been shown as a 
suitable replacement for quantitative nucleic acid detection technologies or to have been evaluated for 
efficacy in resource-limited settings. 
2.1.2.2 Detection of reverse transcriptase activity 
Reverse transcriptase (RT) is an essential component of replication-competent HIV and thus a 
specific marker of HIV infection. The ExaVir
TM
 Load assay (Cavidi Tech AB, Uppsala, Sweden), which 
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is based on the detection of RT activity, was first described by Ekstrand, et al. [38]. This assay requires 
pre-treatment of blood plasma from HIV-positive blood and isolation of the virus on an immobilization 
gel column with subsequent washing to remove anti-RT antibodies or RT-inhibiting antiretroviral drugs 
which are present in many individuals undergoing ART [39], [40]. The sample is eluted from the 
immobilization column by washing with a viral lysis buffer that frees virus-encapsulated RT for assay. 
RT activity is quantified based on incorporation of 5-bromodeoxyuridine 5’ triphosphate (BrdUTP) in RT 
DNA product and subsequent BrdUTP tagging with an alkaline phosphate-conjugated antibody. A 
substrate for AP is then introduced after washing for colorimetric or fluorimetric analysis. The ExaVir
TM
 
assays have been evaluated for sensitivity, practicality and flexibility among various HIV subtypes by 
several clinical studies, including investigations in Burkina Faso [41], Mobmasa, Kenya [31], Botswana 
[42], Nairobi, Kenya [43], and Johannesburg, South Africa [27]. Evaluations appear optimistic toward the 
potential of the ExaVir
TM
 as a less-expensive alternative to PCR [26], [27], [31], [41–49]. 
2.1.2.3. Miniaturization of PCR, non-quantitative 
Several efforts to adapt state-of-the-art testing for resource limited settings has involved 
simplification or automation of various aspects of PCR. For example, Tang et al. developed an isothermal 
amplification kit based on a reverse-transcriptase helicase-dependent nucleic acid amplification technique 
which was integrated with a vertical-flow DNA detection strip [50]. The assay, however, still required 
rigorous preparation of the sample in a laboratory setting, including the purification of viral RNA. Lee et 
al. described an isothermal simple amplification-based assay (SAMBA) that could be performed on a 
table-top point-of-care machine including both amplification and dipstick detection [51]. 
Lee, Kim, Kang and Ahn developed a microfluidic design for on-chip RT-PCR containing mixture 
and reaction chambers for reverse transcription and PCR as well as a detection chamber in which 
amplified product is immobilized on complementary probe DNA [52]. An overview of their microfluidic 
PCR device is depicted in Fig. 4 [52]. An infrared lamp serves as the heart source for PCR thermo cycling 
and immobilized amplified PCR product is tagged with horseradish peroxidase which reacts with 
substrate solution to produce a chemiluminescent product for optical detection. This lab-on-a-chip design 
was capable of performing RT-PCR in 35 minutes, but requires further demonstration of sufficient 
sensitivity and has not been analyzed for quantitative detection. 
2.1.2.4. Miniaturization of PCR, quantitative 
Shen, et al. described the application of a SlipChip device to amplification of HIV RNA [53]. RT-
PCR mixture containing samples is introduced to 160 wells each of 1 nL, 5 nL, 25 nL and 125 nL 
allowing for multiplexed analysis. Correct volumes are ensured by dead-end filling facilitated by 
rotational slipping of a layer of the chip and digital PCR is performed, allowing quantification of viral 
RNA copies. Digital PCR fluorescence on the SlipChip is demonstrated in Fig. 5 [53]. Ultimately, the 
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technique was capable of detecting 37 viral copies per ml plasma although additional demonstration of 
this approach is necessary for consideration as a platform for field testing. 
Rohrman, et al. recently described another gold nanoparticle-based technique for the detection of 
amplified HIV RNA [54]. In their study, NASBA product is placed on a conjugate pad containing gold 
nanoparticles functionalized with complementary RNA strands which bind the sequence of interest. The 
sample flows laterally by capillarity down a nitrocellulose membrane strip to a detection zone in which 
nanoparticle-bound sequences are immobilized. An enhancement solution reduces metallic ions on the 
surface to increase the colorimetric result, which can be assessed with a common cell phone camera. The 
assay is paper-based and is easily destroyed by incineration and is reported to cost approximately $0.80 
per strip, however it relies on amplified nucleic acid and thus does not present a solution to some of the 
most fundamental challenges to implementing PCR-based technologies in resource-limited settings.  
Tanriverdi, et al. adapted a commercially available HIV assay to fit a portable, fully integrated and 
automated diagnostic system called Liat Analyzer [55]. 200 μl plasma is loaded into an assay tube and 
loaded into the analyzer which prepares the sample by performing viral lysis and nucleic acid conjugation 
with magnetic glass beads. The analyzer elutes the viral RNA and performs reverse transcription and PCR 
with real-time fluorescence detection, showing good correlation with COBAS TaqMan HIV-1 and 
Versant HIV-1 RNA (bDNA) assays. The full process is depicted in Fig. 6 [55]. The fully-integrated test 
is completed in 88 minutes and exhibits a limit of detection of 1,000 copies/ml, leaving room for 
improvement to compete with the most rapid and sensitive technologies. 
2.1.2.5. Virus isolation 
In strides toward alternative (non-PCR) approaches to HIV quantification, direct capture of HIV in 
microfluidic flow-through devices has been demonstrated by Demirci, et al. [56–58]. Briefly, a 
microfluidic chamber is functionalized with antibodies specific for the HIV envelope-associated protein 
gp-120 through a variety of surface chemistry techniques and 10 μl [56], [57] or 100 μl [58] of whole 
blood containing HIV was flowed through the device. Captured viruses were initially visualized with 
quantum dot tags to verify capture [56], [57], but in a more recent report were lysed on-chip, collected, 
and interrogated by RT-qPCR for HIV nucleic acid showing 69.7-87.6% capture efficiency for a variety 
of subtypes and viral loads [58].  
In another approach, Chen, et al. mixed virus-containing plasma with superparamagnetic 
nanoparticles functionalized with anti-CD44, an antibody that binds HIV, and injected the sample onto a 
microfluidic chip with geometries designed for mixing [59]. Ferromagnetic particles in the fluidic device 
concentrate an external magnetic field that concentrates virus-bound particles, achieving separation from 
plasma. Isolated sample is then lysed and interrogated for p24 with an ELISA kit, revealing a maximum 
capture efficiency of 79% [59]. An overview of this capture device is shown in Fig. 7 [59]. These 
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platforms, which ultimately could be integrated in a sample-to-answer system, create the opportunity for 
improved sensitivity by removing the virus from whole blood or plasma and thereby eliminating 
contaminants which may interfere with detection. 
2.2 Proviral Load 
2.2.1 Current State of the Art 
Provirus refers to the genome of a virus directly integrated with the DNA of the host cell. The 
proviral load is not as ubiquitous as the plasma viral load or CD4+ T lymphocyte count in clinical 
management of HIV/AIDS, yet it bears certain significance as the standard for early diagnosis of infection 
in newborns for whom mother-to-child transmission is suspected, since serological testing is inadequate 
due to the possibility of false positives from the presence of passively acquired maternal antibodies [3], 
[60–66]Many have also acknowledged that the proviral load may be an opportunity for early detection in 
adults in the 2-8 week window period [67] before seroconversion [61–63], a useful alternative for 
monitoring of ART when plasma RNA levels are undetectable [61], [68], [69], or a complement to the 
plasma RNA load for diagnostic or prognostic purposes [61], [68], [70–73]. Laboratory techniques for 
detection of proviral DNA that have been described including non-quantitative PCR approaches [64], 
[74], quantitative PCR approaches [14], [61], [68], [69], [75], [76], electrochemiluminescence-based 
detection of PCR products [62], enzyme immunoassay detection of PCR products [63], and one study 
which performed PCR analysis on dried blood spots [60]. 
2.2.2 Global Health Solutions 
Jangam, et al. presented a solution to the challenges of sample preparation in resource-limited settings 
when analyzing proviral load with a low-cost extraction technique called filtration isolation of nucleic 
acids (FINA) [77]. In this technique, whole blood is introduced on a membrane disk and subsequently 
washed with NaOH resulting in isolation of genomic DNA on the membrane. The membrane is then 
placed directly in a PCR reaction mix for quantitative analysis. Recently, the same group has reported 
integration of this extraction method with a sample-to-answer point-of-care PCR system for proviral 
DNA detection [78]. In this case, blood collected from a heel prick is lysed in the blood collection device, 
applied to a separator module for FINA, and inserted into an injection-molded assay card. The assay card 
contains reagents for PCR prepackaged in a foil laminate reagent reservoir and the entire card it inserted 
directly into a table-top instrument which performs reagent delivery, thermal cycling and fluorescence 
detection. The estimated cost of the instrumentation is $3,000.00 while each disposable assay card is 
expected to cost $50.00 or less, a per-test cost on the higher end of the range of estimates reported in the 
approaches discussed in this review. 
Wang, et al. have also recently described a device capable of proviral DNA detection on a chip [79]. 
In this proof-of-concept, HIV-infected T cells were loaded onto the chip where they were first heat-lysed 
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and then hybridized with nucleotide probe-conjugated magnetic beads. A permanent magnet was then 
used to immobilize probes while debris was cleared with a vacuum and the sample was washed. Purified 
sample was then split between four separate chambers containing unique primer pairs, and PCR 
amplification was performed and monitored by SYBR Green I fluorescence and integrated optical 
detection. The whole process was completed in 95 minutes, demonstrating potential for implementation 
as a point-of-care device in resource-limited settings, although demonstration of this technique from 
whole-blood input would be necessary for truly point-of-care applications. 
2.3 CD4+ T Lymphocyte Count 
2.3.1 Current State of the Art 
The current gold standard for enumeration of CD4+ T lymphocytes involves immune-staining and 
analysis of cells with a flow cytometer, a technique that not only requires expensive and bulky 
instrumentation but also highly-trained laboratory technicians. In efforts to bring CD4 enumeration to 
resource-limited settings, various techniques have been employed. Here we organize various technologies 
for CD4 enumeration in resource-limited settings based on the following categories: optical detection 
methods, electrical detection methods, technologies based on microcytometry employing either optical or 
electrical techniques, catch-and-release devices, and instrument-free methods. 
2.3.2 Global Health Solutions 
2.3.2.1 Optical methods 
Many efforts have used fluorescent tagging and subsequent image processing to automatically 
enumerate CD4+ T lymphocytes in micro chambers. Some designs relied on the even distribution of cells 
in a plastic chamber to produce accurate counts [80]. Others have used a micro fabricated membrane to 
filter out erythrocytes, leaving leukocytes, which were fluorescently labeled [81]. Specialized image 
processing algorithms have been developed for the analysis of images from such devices [82]. Thorslund 
et al. developed and refined a bio-activated PDMS device for capture of CD4+ cells and subsequent 
imaging with HOECHST and CD3-FITC [83], [84]. 
Fluorescence detection was later enhanced by using quantum dots [85], [86], forming the technology 
behind LabNow, Inc. Another approach used immuno-specific paramagnetic beads to bring fluorescently 
labeled CD4+ T cells into the focusing plane for analysis, reducing counting error [87–89]. Cheng et al. 
have investigated CD4+ T cell capture by controlling shear stresses at the chamber walls and enumerating 
cells using a cocktail of fluorescently labeled antibodies [90], [91]. They improved their design by 
including a monocyte depletion chamber to reduce the positive bias created at lower CD4+ T cell 
concentrations [92]. 
Beck et al. have eliminated the off-chip labeling step required by the aforementioned methods by 
coating capture chambers with hydrogels containing fluorescent antibodies and drying them for storage 
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[93]. During testing, blood enters the capture region, causing the hydrogel to swell and release the 
antibodies, specifically labeling CD4+ and CD8+ T cells. Subsequent fluorescent image cytometry is used 
to obtain the CD4+ and CD8+ T cell counts. The Alere Pima CD4 counter uses a similar method to label 
CD4+ T cells using cartridges containing a lyophilized antibody pellet [93], [94], and has shown some 
success in field testing including sites in Harare, Zimbabwe [95], Maputo, Mozambique [96], Gauteng 
Province, South Africa [97], Kampala, Uganda [98] and London, UK [99]. However, in some situations, 
it has operational costs similar to or more expensive than standard lab flow cytometric analysis [97], 
[100]. 
The aforementioned optical methods require the use of lenses and focusing to analyze samples, but 
this can increase the cost and decrease the portability of the device and several technologies have made 
attempts at simplifying the optical component. Gohring et al. quantified the antibody-mediated attachment 
of T cells by the amount of shift in the whispering gallery mode of an optofluidic ring resonator [101]. 
Moon et al. counted immobilized helper T cells by their shadows cast over a charge coupled device 
(CCD) by a white light source [102], [103]. Wang et al. further simplified the optics by not requiring an 
external light source: immobilized CD4+ T cells were labeled with CD3-conjugated horseradish 
peroxidase to facilitate a chemiluminescent reaction, which was amplified and quantified by a 
photodetector [104]. This device was tested using samples from patients at a treatment center in Dar es 
Salaam, Tanzania [105]. 
2.3.2.2 Electrical methods 
Electrical methods for enumerating CD4+ T lymphocytes are promising due to the fact that they 
would not require optical components such as lenses, filters, light sources, photodetectors, and CCDs, 
which can be expensive, bulky, fragile, and require periodic maintenance. An electrical PoC solution 
could require only solid state components to electrically interrogate a sensing geometry, process sensor 
output, and provide input from and results to the user. 
Mishra et al. used three-electrode cyclic voltammetry to estimate the number of CD4+ T cells that 
were selectively captured on a working electrode [106], [107]. Jiang et al. have used this design as a 
building block to create an array of 200 of these electrochemical sensing regions, or pixels, conjugated 
with CD4 antibody. A pixel would be considered on when a CD4+ T cell was captured, and a total cell 
count was the total number of on pixels [108]. 
Cheng et al. enhanced their CD4+ T cell capture device ([90], [91]) by integrating impedance 
spectroscopy sensing into the capture channel to monitor cell lysate [109]. T cells from whole blood were 
captured on-chip and lysed in a low-conductivity buffer, releasing intracellular ions into the bulk solution, 
thereby changing its conductance, which increased proportionally with cell concentration. Impedance-
phase spectra and correlation with cell concentration are shown in Fig. 8 [109]. The authors were able to 
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correlate cell concentration with channel conductance with a detection sensitivity of 20 cells/uL, 
eliminating the need of a microscope and manual cell counting. Daktari Diagnostics, Inc., has developed 
the Daktari CD4 counting platform based on this technology. 
The lysate impedance method has shown to be an extremely promising technology to penetrate into 
resource poor regions, as it requires no off-chip sample preparation, employs an electrical interrogation 
method, and is simple to operate. However, inherent drawbacks from measuring lysate impedance may 
reduce its efficacy. This technology assumes that T cells from various individuals contain similar ion 
concentrations, which may not be true, resulting in counting error. In addition, since the technology is 
sensitive to the concentration of ions, contamination from the sensor chip's materials and failure to wash 
away excess ions may reduce the system's counting resolution and dynamic range. 
2.3.2.3 Microcytometer approach 
Kiesel et al. worked toward the goal of a compact flow cytometer with a spatial modulation technique 
for CD4 identification [110]. Wang et al. have developed a microfluidic chip which first labels CD4+ and 
CD8+ T lymphocytes (from buffy coat samples) on-chip using pneumatic vortexing before 
hydrodynamically focusing and laser-induced fluorescence (LIF) counting [111]. They were able to 
produce CD4/CD8 T cell ratios similar to that found using standard flow cytometry. Yun et al. developed 
a microfluidic flow cytometer enhanced by FITC-doped silica nanoparticles that required only a single 
detector [112]. Mao et al. designed a microfluidic flow cytometer with three-dimensional hydrodynamic 
focusing of CD4+ T lymphocytes and LIF detection [113]. 
Wang et al. integrated a commercial metal oxide semiconductor field effect transistor (MOSFET) 
with optical fluorescence detection to determine the percent of CD4+ T cells among a total population of 
lymphocytes [114]. They have also created a similar system replacing the MOSFET with a two-stage 
differential amplification system [115], [116]. However, the added complexity of integrating both 
electrical and optical measurement systems may be prohibitive for PoC applications. 
Holmes et al. have developed an electrical microcytometer that can differentiate between different 
leukocyte subtypes, such as lymphocytes, monocytes, and neutrophils, solely on their impedance 
characteristics at two different frequencies, as depicted in Fig. 9 [117], [118]. They were subsequently 
able to enhance electrical differentiation of CD4+ T cells from other leukocytes by specifically attaching 
2.2 μm CD4 antibody conjugated latex beads to the T cells to modify their high and low frequency 
characteristics [119]. They showed good correlation between their electrical chip-based method and the 
flow cytometry standard for the percentages of CD4+ T cells in white blood cell populations. However, 
the off-chip bead labeling steps they used would need to be integrated into the chip itself for this 
technology to be practical in resource-poor applications – a task that is difficult to perform in the laminar 
flow regime found at the microscale. 
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Watkins, et al. developed an impedance-based microcytometer for determining CD4 T cell counts 
employing a resistive pulse technique [120]. Cells were initially focused in a three-dimensional flow 
sheath for one-by-one flow past a pair of coplanar electrodes and subsequent analysis of AC impedance 
indicated cell passage by a impedance pulse. A coplanar three-electrode configuration was implemented 
in a later device which incorporated entrance and exit counting as white blood cells were passed through 
an anti-CD4 antibody-functionalized capture chamber as illustrated in Fig. 10 [121]. CD4+ T cells were 
depleted from the sample by immobilization in the capture chamber and the absolute CD4 count was 
provided by the difference between entrance and exit counts. 
2.3.2.4 Catch-and-release 
Chemical release of CD4+ T cells post capture has proven to be more difficult, as the cells may 
further bond to the substrate nonspecifically through membrane adhesion molecules. Zhu et al. have 
shown the capture and release of CD4+ T cells using electrochemical reactions on microfabricated 
electrodes; however some drawbacks are that some cell death occurs after T cell release (~10%) and 
agitation is needed to assist in electrochemical desorption, which is more difficult in the laminar flow 
regime found in a closed microfluidic chamber [122], [123]. In addition, mass production may be 
hindered by the fact that the capture region is limited to the area defined by the electrodes, requiring a 
PEG gel passivation layer elsewhere to prevent non-specific cell capture. 
Gurkan et al. used a temperature responsive polymer to capture and release CD4+ T cells [124]. A 
capture chamber coated with poly(N-isopropylacrylamide) (PNIPAAm) was immobilized with CD4 
antibody-Neutravidin complexes at 37 degrees C – when the polymer is hydrophobic and prefers 
interactions with the Neutravidin. CD4+ T cells are captured at the same temperature before washing 
away unbound cells and lysing erythrocytes. The CD4+ T cells are released by decreasing the chip's 
temperature below 32 degrees C, when the PNIPAAm layer becomes hydrophilic, releasing the antibody-
Neutravidin complexes and thereby releasing the CD4+ T cells. They were able to release 59% of 
captured CD4+ T cells with high viability (94%). This method needs to address a few challenges before 
being a practical PoC device. This includes ensuring surface chemistry is preserved from manufacture to 
test (i.e., storing the chips at ~37 deg C) and improving the release efficiency for accurate CD4+ T cell 
enumeration. 
2.3.2.5 Instrument-free methods 
Since 2005, the Bill and Melinda Gates Foundation has been funding a CD4 initiative (centered at 
Imperial College London) to create simple, power-free CD4+ T cell counting technologies that would 
lessen costs and increase penetration into resource-poor regions [125]. A semiquantitative 
immunochromatographic strip (ICS) being developed by The Burnet Institute compares the intensity of 
gold particles that are specifically attached to CD4+ T cells at a CD4 capture strip to a reference strip 
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which has a similar intensity to a known concentration of CD4+ T cells [126]. Zyomyx has developed a 
device that uses the sedimentation of high density CD4 antibody-conjugated beads to estimate the 
concentration of CD4+ T cells from whole blood samples [126], [127]. These beads specifically attach to 
the CD4+ T cells and are sedimented with the help of a manually powered centrifuge. The height of 
sedimentation in the column is proportional to the concentration of CD4+ T cells, and is viewed through a 
window and compared to calibrated markings to give the CD4+ T cell count. The device also contains a 
chamber which used CD14-conjugated magnetic particles and a magnetic collar to deplete monocytes 
before the sedimentation step. These semi-quantitative instrument-free methods may be viewed as short-
term solutions, but fully-quantitative micro- and nanotechnology solutions promise more precise and 
user-friendly approaches. 
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Tables 
 
Table 1. FDA-approved tests for plasma viral load quantification 
Test name [17–19] Manufacturer FDA Approval [18], [20] Type 
Roche Amplicor HIV-1 Monitor Test Rochem Molecular Systems, Inc. 3/2/1999 RT-PCR 
NucliSens HIV-1 QT bioMerieux, Inc. 11/19/2001 NASBA 
VERSANT HIV-1 RNA 3.0 Assay (bDNA) Bayer Corporation, Berkeley, CA 9/11/2002 bDNA 
Abbott RealTime HIV-1 Amplification Kit Abbott Molecular, Inc. 5/11/2007  RT-PCR 
COBAS TaqMan HIV-1 Test Roche Molecular Systems, Inc. 5/11/2007 RT-PCR 
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Figures 
 
 
Fig. 3. Biobarcode assay for the detection of HIV p24 antigen. Reprinted from Ref. [34] with permission 
from Lippincott Williams & Wilkins, Inc. 
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Fig. 4. Polymer-based device for on-chip PCR. Reproduced from Ref. [52] with permission from The 
Royal Society of Chemistry. 
 
 
Fig. 5. Digital RT-PCR results on a rotational SlipChip. Reprinted with permission from Ref. [53] 
Copyright 2011 American Chemical Society. 
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Fig. 6. Overview of Liat analyzer. Reprinted from Ref. [55] with permission from Oxford University 
Press. 
 
 
Fig. 7. Superparamagnetic nanoparticle capture device. Reprinted with permission from Ref. [59]. 
Copyright 2009 American Chemical Society. 
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Fig. 8. Cell lysate impedance spectroscopy for enumeration of CD4 T lymphocytes. Reprinted from Ref. 
[109] with permission from The Royal Society of Chemistry. 
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Fig. 9. Leukocyte type differentiation by dual-frequency impedance characteristics. Reprinted from Ref. 
[117] with permission from The Royal Society of Chemistry. 
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Fig. 10. Differential counter technique for CD4+ T cell enumeration. Reprinted from Ref. [121] with 
permission from The Royal Society of Chemistry. 
This text originally appeared in Damhorst GL, Smith CE, Salm EM, Sobieraj MM, Ni H, Kong H, Bashir 
R, “A liposome-based ion release impedance sensor for biological detection,”(submitted manuscript). 
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3. Materials and Methods  
The point-of-care detection of biological entities will play an essential role in the changing face of 
health care delivery by making the detection of disease and monitoring of treatment more ubiquitous in 
developed nations and more accessible in developing nations. Sensing platforms for biomolecular entities 
such as cardiac enzymes, cancer biomarkers, toxins, bacteria and viruses can dramatically improve 
clinical outcomes by enabling earlier diagnosis and personalized monitoring. In particular, populations 
residing in remote and resource-limited settings stand to benefit significantly from low-cost portable 
technologies capable of detecting the mediators of major communicable diseases. 
As an example, 34 million people worldwide are living with human immunodeficiency virus (HIV), 
the virus that causes acquired immune deficiency syndrome (AIDS) and led to 1.8 million deaths in 2010 
alone [1]. Among the greatest challenges in fighting HIV/AIDS globally is access to adequate healthcare 
in the world’s poorest regions which are disproportionately affected by the epidemic [1]. This includes 
access to antiretroviral therapy as well as the diagnostic technologies required to inform administration of 
that therapy. The gold standards, flow cytometry for CD4+ T lymphocyte counting and nucleic acid 
amplification (PCR, NASBA, or bDNA assays) for determination of plasma viral load, require expensive 
instrumentation, skilled technicians, and lack the portability necessary to be employed in in remote and 
resource-limited settings. Furthermore, while it has been shown that early administration of therapy is 
critical to outcome [128], diagnosis of HIV status in adults is limited by the 2-8 week window period 
during which standard serological assays can produce false negatives [67]. A more accessible test for 
detecting HIV more immediately after infection could make great strides in combating the disease. 
A critical need therefore remains for a low-cost HIV detection assay for the point-of-care which could 
provide (i) a qualitative assessment of plasma viremia, especially during the early weeks of infection prior 
to seroconversion, and (ii) a quantitative assessment of plasma viral load as a tool for informing treatment 
strategies in individuals with established HIV-positive status, especially during initial viremia when 
antibodies are undetectable but plasma viral load is in the range of 10
6
 copies/ml [129]. 
Several micro- and nanotechnology solutions have been described in attempts toward point-of-care 
platforms for HIV/AIDS diagnostic applications [130]. These approaches have often included assays for 
the p24 viral capsid protein [32–36] and viral enzyme reverse transcriptase activity [38]. Others have 
attempted isothermal amplification of viral nucleic acid on point-of-care platforms [50], [51] or 
miniaturized polymerase chain reaction (PCR) [52], [53], [55]. Few approaches have attempted detection 
of whole virus particles for a point-of-care measurement, although strategies for the separation of HIV 
from whole blood or plasma for diagnostic assays by microfluidic immunoaffinity chromatography [56–
58] and superparamagnetic nanoparticles [59] have been reported and may lend themselves well to a 
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whole particle detection approach. Many of the approaches reported to date, however, are not fully 
portable and automated, rely on expensive detection instrumentation, or do not demonstrate the sensitivity 
necessary to rival state-of-the-art nucleic acid amplification assays, thus a ubiquitous platform for point-
of-care HIV viral load detection is yet to emerge. 
The concept of lysate impedance spectroscopy was introduced by Cheng, et al. for the detection of 
human CD4+ T lymphocytes [109]. Cells were captured in a microfluidic channel and lysed by the 
addition of low-conductivity hypotonic solution and impedance changes detected by surface electrodes 
were showed to be indicative of cell number down to just 20 cells μl-1. Others have applied impedance 
spectroscopy more broadly for the detection of bacterial growth, [131], [132] binding of an analyte to a 
recognition site on electrodes [133], and, recently, the qualitative detection of HIV from viral lysis at high 
concentrations [134]. 
The concept of releasing liposome contents as a biosensor component has been reported in the past; 
however, the materials encapsulated by the liposomes in these cases were either fluorescent molecules or 
redox couples [135–141]. Our ion-encapsulating liposomes represent a simpler approach which would 
better accommodate the requirements for portable sensing platforms. 
Here we report an ELISA-inspired approach to biological detection consisting entirely of on-chip 
electrical impedance sensing and apply to HIV detection. At the core of this detection strategy is a 
micron-sized, antibody-functionalized liposome particle encapsulating concentrated phosphate buffered 
saline (PBS). These liposome tags can be quantified by impedance spectroscopy upon ion release in low 
conductivity media and are also shown to specifically bind surface-immobilized virus particles captured 
in a microfluidic channel. Here we characterize dipalmitoylphosphatidylcholine (DPPC) liposome 
particles, show quantification by this electrical sensing method, and demonstrate an ELISA-like approach 
to virus capture, liposome tagging and sensing. 
3.1 Modelling of impedance spectroscopy 
3.1.1 Conductivity changes from liposome ion release 
The change in impedance sensed by our system is the result of ion release into the surrounding media 
from the permeabilization of liposomes. The average diameter of liposomes used in this report (see Fig. 
11) was determined to be 3.7 μm, which corresponds to an average volume of 26.5 fL per liposome. Each 
liposome encapsulated 10X PBS containing 1.37 M NaCl and 0.027 M KCl. Each liposome therefore 
contributes approximately 3.6 × 10-14 moles of NaCl to the surrounding media upon complete release of 
its contents. Assuming that the beginning solution is true deionized water (conductivity of 0.055 MΩ-1 
cm
-1
) [142], 33,000 liposomes (~5,000 liposomes per μl) would produce a 0.18 mM change in NaCl in the 
6.628 μl volume fluidic channel. Assuming the effects on conductivity of NaCl in 10X PBS dominates 
over the effects of KCl, this change in ion concentration can be calculated to produce a change per 
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liposome per microliter of approximately 4.27 GΩ-1 cm-1 [142], [143]. It has been shown previously that 
change in capacitance from ion release into solution is several orders of magnitude lower than the change 
in bulk conductance, thus the effect on conductance dominates [109]. 
3.1.2 Modelling impedance spectra 
Electrodes in solution can be modelled by the equivalent circuit in Fig. 14d. In this simplified model, 
Cdi is the dielectric capacitance resulting from all materials surrounding the electrodes, Rsol is the solution 
resistance, Rser is the series resistance of the electrodes and wires, and Zpara is the parasitic impedance, 
which is measured from the open circuit [109], [131], [132]. Zdl, the interfacial or Warburg resistance, is 
described by 
    Zdl = [(jω)nB]
-1
 (1) 
Where j = √(-1), and the parameters n and B depend on the properties of the electrolytes and electrodes 
[109], [131], [132]. This model will be used to fit the impedance spectra of liposome ion release in the 
interdigitated electrode device described here. 
3.2 Reagents 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-{12-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]dodecanoyl}-sn-glycero-3-phosphocholine (NBD PC)  were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Protein A was purchased from ProSpec (East Brunswick, NJ, 
USA). Phosphate buffered saline (10X solution) was purchased from Fisher Scientific (Hampton, NH, 
USA) and Lonza (Basel, Switzerland). Sucrose, dextrose and Triton X-100, deoxycholic acid, sodium 
azide palmitic acid N-hydroxysuccinimide (pal-NHS), and rhodamine B isothiocyanate were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Calcein was purchased from Fisher Scientific (Hampton, NH, 
USA). Anit-gp120 goat IgG was purchased from Abcam (Cambridge, MA, USA). Virus buffer consisted 
of Tris, NaCl, and EDTA purchased from Sigma-Aldrich (St. Louis, MO, USA). HIV-1 strain IIIB was 
purchased from Advanced Biotechnologies Inc. (Columbia, MD, USA). 
3.3 Preparation of liposomes 
DPPC was dissolved in chloroform and dried in a round bottom flask by rotary evaporation. The lipid 
film was hydrated with 10X PBS at 50 degrees C to create liposomes at a lipid concentration of 1 mg/ml. 
This mixture was then sonicated for 15 minutes in an ice bath. 
To create fluorescent NBD-liposomes, NBD-PC lipids were dissolved with DPPC at 1 mol%. 
Liposomes were then formed by the same hydration and sonication processes described above. 
3.4 Devices 
Planar interdigitated electrode chips were fabricated on glass with standard photolithography and gold 
lift-off technique. A polydimethylsiloxane (PDMS) cover 4 mm x 34 mm x 50 μm (6.628 μl total volume) 
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was cured on a master mold of SU-8 photoresist patterned on a 4” silicon wafer using standard 
photolithography technique. Inlet and outlet ports were punched in each PDMS cover, which were then 
aligned with the electrodes and bonded after oxygen plasma activation in a barrel etcher. A schematic and 
photograph of the device are provided in Fig. 11. 
3.5 Liposome stability characterization 
NBD-liposomes were prepared in 10X PBS as described above. Initially, four samples were each 
added to deionized (DI) water, centrifuged at 3220 rcf for 10 minutes to pellet the liposomes, and the 
supernatant was aspirated. The pellet was then re-suspended in DI water and the process was repeated to 
achieve thorough washing. After the second aspiration of supernatant, each pellet was re-suspended in 
10X PBS, 1X PBS, sugar solution, or DI water. Each sample was well-mixed by pipetting up and down to 
ensure even re-suspension of the pellet and placed on a sample rotisserie to prevent settling. Liposome 
number was assessed regularly for each sample by a Guava EasyCyt Plus flow cytometer (EMD 
Millipore, Billerica, MA, USA) over the course of several hours. 
To consider the effects of detergent on liposome stability, NBD-liposomes were washed as described 
above and re-suspended in DI water or DI water containing 1% v/v Triton X-100. Samples were placed 
on a sample rotisserie and analysed by flow cytometry over the course of several hours. 
To consider the effects of heating on similar samples, NBD-liposomes were washed and re-suspended 
in DI water or 1% v/v Triton X. Each sample was aliquoted into several vials which were independently 
heated to temperatures ranging from 30 degrees C to 99 degrees C. After heating and cooling to room 
temperature, liposomes were analysed in a flow cytometer to determine liposome number.  
3.6 Liposome permeability characterization 
Liposomes were prepared in 10X PBS containing 50 mM calcein and washed twice by adding an 
equal volume of DI water, centrifugation and aspiration of supernatant. After the second wash, liposomes 
were re-suspended in 10X PBS, 1X PBS, sugar solution, or DI water and added as eight replicates of each 
sample in 0.2 ml PCR reaction tubes. This reaction strip was placed in a Mastercycler ep realplex real 
time PCR system (Eppendorf, Hauppauge, NY, USA) for temperature analysis. The sample temperature 
was increased from 25 degrees C to 95 degrees C over 30 minutes and at 520 nm emission was monitored 
throughout. Control samples containing 10X PBS without calcein were also analysed in the same assay. 
3.7 Heat-induced liposome permeabilization for impedance spectroscopy 
NBD-liposomes were washed and re-suspended in DI water in four different concentrations. Serial 
dilutions of each of these liposome suspensions were performed in DI water to achieve the desired range 
of liposome number. A dilution within the range of the flow cytometer was analysed to determine 
liposome concentration for each of the four sample sets. Samples were heated to 50 degrees C for 15 
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minutes and allowed to cool to room temperature. Each sample was then injected into the interdigitated 
electrode chip for impedance spectroscopy analysis. 
3.8 Impedance spectroscopy measurements 
Impedance magnitude and phase angle were determined using an Agilent 4284 LCR meter (Agilent 
Technologies Inc., Palo Alto, CA, USA). Micromanipulator probes were used to connect the 
microfabricated device to the LCR meter and the measurement process was automated by MATLAB 
(MathWorks, Natick, MA, USA). Impedance spectra were measured for frequencies between 100 Hz and 
1 MHz with an increase factor of 1.5 and amplitude of 250 mV. 
3.9 Real-time impedance monitoring of ion release from liposomes 
NBD-liposomes were prepared and washed as described previously. However, to ensure complete 
elimination of ionic contamination from liposome samples, each wash was performed in a 50 ml 
centrifuge tube and repeated twice for a total of three washes. Liposomes were then suspended at various 
solutions and a portion of the sample was immediately analysed by flow cytometry to determine liposome 
number. Within one minute of re-suspension in DI water, the liposome sample was injected into the 
interdigitated electrode device. The device was set on a heating stage and held at 23 degrees C for 30 
seconds before being heated to 50 degrees C and held for several minutes. Impedance was monitored 
throughout at 2 kHz and 10 kHz. 
3.10 Preparation of antibody-functionalized liposomes 
Protein A was hydrophobically modified with hexadecyl chains for anchoring on the liposome 
surface. Briefly, 1mg of protein A was reacted with 0.1 mg of pal-NHS in a solution of 0.3% deoxycholic 
acid and 0.1% sodium azide in 1X PBS according to the procedure described by Kim and Peacock [144]. 
After reacting for 24 hours at room temperature, palmitated protein A was purified by centrifuge filter 
(MWCO 3kDa, Millipore). 
Protein A was adsorbed to liposomes by mixing 5 μg of palmitate-modified protein A for every 1 mg 
of lipid. The mixture was incubated for 12 hours at room temperature, followed by addition of DI water to 
pellet the liposomes upon centrifugation for 10 minutes at 3220 rcf to remove protein A that was not 
adsorbed. 
To verify adsorption of protein A, the protein was fluorescently labeled with the amine-reactive 
rhodamine B isothiocyanate, followed by purification by centrifugal filtration and dialysis to remove 
unreacted rhodamine. This fluorescent palmitated protein A was incubated with liposomes, which were 
then purified by centrifugation as described. Fluorescent intensity of the supernatant and re-suspended 
liposomes was recorded with a Tecan Infinite 200 PRO (Tecan AG, Switzerland), indicating that 40% of 
the protein A initially added remained adsorbed to the liposomes. 
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Liposomes with protein A were then mixed with 18 μg/ml anti-gp120 IgG for four hours on a sample 
rotisserie. 
3.11 Virus detection by heat-induced liposome permeabilization 
Interdigitated electrode devices were infused with 25 μl of 0.3 mg/ml anti-gp120 IgG in PBS and 
incubated at 4 degrees C overnight. Excess antibody was rinsed from the fluidic chamber with 100 μl PBS 
flowing at 10 μl min-1. Following this rinse, 50 μl buffer containing 6.7e11 virus particles per μl or buffer 
without viruses was infused into each device at 5 μl min-1 and incubated for approximately four hours. 
Following incubation, each device was rinsed with 100 μl PBS at 10 μl min-1 to remove the buffer and 
unbound viruses. Subsequently, 100 μl of 6,537±70 μl-1 liposomes functionalized with anti-gp120 IgG 
were injected at a rate of 10 μl min-1 followed immediately by rinsing with 200 μl DI water at 20 μl min-1 
to rinse away unbound liposomes and lower the conductivity of the bulk solution. Each device was then 
placed on a heating stage and real-time impedance was measured during heating as described above. 
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Figures 
 
 
Fig. 11 (a) Schematic of interdigitated electrode impedance sensing device. Each electrode finger is 15 
μm wide with a 35 μm gap between electrodes. Labeled components are (i) gold contact pads where 
micromanipulator probes contact the device, (ii) sensing region/fluidic chamber, (iii) fluidic inlet port, 
(iv) fluidic outlet port. The blue region represents the fluidic chamber defined by the PDMS cover. (b) 
Photograph of device with PDMS cover mounted on a microscope slide. Micromanipulator probes can be 
seen in contact with the device. (c) Histogram of liposome diameters as determined by optical microscopy 
(mean diameter = 3.682 μm, standard deviation = 2.262 μm) and analysis with ImageJ software. (d) 
Illustration of liposome sensing concept: (i) liposomes are hydrated in 10X PBS, producing ion-
encapsulating particles, (ii) the external media is replaced with low-conductivity DI water, (iii) ion release 
is triggered and impedance change is measured in order to quantify liposomes present in the sensing 
device.
This text originally appeared in Damhorst GL, Smith CE, Salm EM, Sobieraj MM, Ni H, Kong H, Bashir 
R, “A liposome-based ion release impedance sensor for biological detection,”(submitted manuscript). 
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4. Results and Discussion 
4.1 Liposome stability characterization 
To determine the stability of liposomes in various media, flow cytometry measurements were 
recorded over several hours with NBD-liposomes. Three replicates each of liposomes suspended in 
isotonic (10X PBS) and hypotonic (1X PBS, sugar solution, DI water) media were measured to assess the 
effects of various osmotic forces. Sugar solution was chosen because it has been used in the past as an 
approach to maintaining lymphocyte stability when a low-conductivity medium is desired for impedance 
measurements of cell lysate [109]. The 8.5% sucrose/0.3% dextrose solution used in these measurements 
would have approximately the same osmolarity as cytosol or 1X PBS. A sugar solution which matches 
the osmolarity of 10X PBS is not practical (too viscous) and therefore was not investigated. 
Flow cytometry analysis of liposomes in the four media considered showed little to no decrease in 
both PBS samples and some depletion in both sugar and DI water over approximately fourteen hours. To 
analyse the counting data for each sample, each replicate was fitted separately and the three fits were 
averaged. This averaged fit is presented in Fig. 12a. The slope of the fits showed depletion rates of 
approximately 0.0905% min
-1
, 0.0569% min
-1
, 0.0089% min
-1
, and 0.0125% min
-1
 for DI water, sugar 
solution, 1X PBS and 10X PBS respectively (Fig. 12a, inset). 
In order to compare the stability of liposomes in DI water with a common liposome 
permeabilization/lysis reagent, Triton X-100, a separate flow-cytometry measurement was performed 
with liposomes in DI water and 1% Triton X. In this case, liposomes with and without membrane-
integrated protein A were also compared to determine if liposome functionalization would compromise 
stability. The results, presented in Fig. 12b, show that liposomes are compromised in the presence of 
detergent, showing rapid depletion in the first hour and nearly 100% depletion of liposomes after five 
hours. The presence of adsorbed protein A showed little effect. 
Upon initial consideration of heating as a chemical-free permeabilization technique for liposome 
impedance sensing, liposomes in DI water and 1% Triton X were also analysed by flow cytometry after 
heating to various temperatures. Counting data in Fig. 12c shows that the destabilizing effects on the 
liposomes of detergent were accelerated by the addition of heat to the solution. A proposed mechanism 
explaining the behavior of liposomes upon heating and in the presence of detergent is provided in the 
Discussion section of this paper. 
4.2 Effects of heat on liposome stability 
A DNA melting curve assay proved to be the ideal measurement for characterizing the effects of 
heating on liposome stability and to determine the critical temperature, which we define as the 
temperature at which the lipid bilayer is partially compromised and encapsulated contents are released 
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into the surrounding media. An ideal reporter molecule for this measurement was calcein, a fluorescent 
dye which self-quenches at millimolar concentrations [145], [146]. 
Liposomes were prepared in concentrated calcein and removed from free calcein in surrounding 
media by centrifugation and re-suspension of the liposome pellet. Calcein encapsulated within liposomes 
exhibited very little emission at 520 nm. Upon heating in the thermocycler, however, a sharp increase in 
fluorescence is observed in the range of 40-43 degrees C, indicating the release of liposome contents as 
calcein dissociates and self-quenching subsides. A plot of raw fluorescence is presented in Fig. 13a, with 
the first derivative with respect to temperature, dI/dT, presented in Fig. 13b as reported by the 
instrument’s data analysis software. 
4.3 Liposome quantification by ion-release impedance spectroscopy 
The quantification of liposomes by impedance spectroscopy was demonstrated by suspension of 
liposomes at various concentrations in DI water and off-chip heating to promote release of encapsulated 
ions. After cooling to room temperature, each sample was injected into the fluidic chamber and 
impedance spectra were measured. The measured impedance depends on the concentration of ions in the 
fluid. We assume the average liposome size is consistent between measurements and that all liposomes 
encapsulate 10X PBS, which allows for impedance to be directly related to liposome number. Figs. 14a-b 
show the impedance magnitude and phase angle versus AC frequency for each sample. In Fig. 14c, the 
impedance recorded at 2.6 kHz is plotted versus liposome concentration as measured by a flow cytometer. 
A lower limit of detection was determined to be at a liposome concentration of approximately 103 μl-1 
and impedance values measured at concentrations above this were fitted with a straight line on log-log 
axes. 
4.4 Impedance modelling 
The simplified circuit model in Fig. 14d was used to fit measurements displayed in Figs. 14a-b. The 
parasitic impedance Zpara was determined by fitting the impedance data measured with the device prior 
to adding any fluid and was then held constant for the other fits. Examples of fits with the measured data 
are provided in Figs. 14e-f. The bulk conductance Gsol = 1/Rsol can be determined from the parameters 
extracted for each measurement and are plotted in Fig. 14g versus liposome concentration [109]. The 
slope of the fit to conductivity data gives the sensitivity of the interdigitated electrode chip, determined in 
this case to be 16.022 GΩ-1 (liposomes per μl)-1 [109]. 
4.5 Real-time impedance monitoring and quantification 
Ion release from liposomes was monitored in real time and the resulting impedance trace could be 
used to determine liposome concentration as described above. 10X PBS-containing liposomes in DI water 
were injected into the interdigitated electrode device which was placed on a small heating stage. The 
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temperature was held constant near room temperature for 30 seconds and quickly increased to 50 degrees 
C where it was held constant until the measurement completed. Because conductivity increases with 
temperature, the impedance trace shows an initial steady decrease as a result of heating of the device; 
however, a second, sharper decrease is observed as the device reaches critical temperature and the 
encapsulated ions are released. Sample traces of this behavior are presented as the normalized impedance 
over time in Fig. 15a and the time derivative of normalized impedance in Fig. 15c. Figs. 15b and 15d 
show two methods for quantifying liposomes from this data: by fitting the normalized impedance after 
200 seconds (Fig. 15b) and by determining the maximum rate of change (Fig. 15d). Once again, the 
signals produced by samples below concentrations of 10
3
 ml
-1
 appear commensurate with measurements 
of DI water and are not included in fitting of the data. 
4.6 Virus detection 
As a proof-of-concept toward liposome ion-release impedance spectroscopy for virus detection, 
several devices were functionalized with anti-gp120 antibody and exposed to 6.7e11 μl-1 HIV to be 
compared with controls. After prolonged exposure to the virus, the devices were rinsed and 100 μl of 
IgG-functionalized liposomes (6,537±70 μl-1) in PBS were injected through the device, followed 
immediately by rinsing with 200 μl DI water. A schematic of this ELISA-like assay is depicted in Fig. 
16a. The same heating and real-time impedance monitoring protocols as described above were followed 
for analysis of these devices, and the normalized impedance after 200 seconds for devices prepared with 
immobilized viruses is compared with a control treated with virus-free buffer. Fig. 16b shows the 
normalized impedance data and Fig. 16c summarizes data from four separate devices for each case, 
showing a significantly larger change in impedance after 200 seconds for virus-containing devices, 
representing specific capture of liposomes on immobilized HIV. 
4.7 Discussion 
This paper describes progress toward an ELISA-like liposome-based impedance sensing device for 
biological sensing at the point-of-care. We begin with the characterization of liposome particles 
containing 10X PBS which are the basis for electrical sensing, providing a simple and low-cost solution 
to detection of submicron particles. Liposome stability over time is compared in four different media, 
demonstrating that although liposome depletion rate is greatest in DI water as the result of osmotic forces, 
the loss of particles is still minimal over a short time span. In our assay, the exposure of liposomes to pure 
DI water is anticipated to be 10 minutes or less, thus this minimal depletion rate is inconsequential. This 
is a marked difference from the effects of DI water on human T lymphocytes where it was used by Cheng, 
et al. to promote rapid lysis of human cells [109]. 
Liposome stability in DI water was also compared to stability in the presence of the detergent Triton 
X, a reagent which is used ubiquitously to restructure lipid membranes. We believe that the detergent 
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disrupts the liposomes by inserting itself into the lipid bilayers, thus increasing permeability. At a 
constant temperature, rupture of the entire liposome population appears to occur over several hours and 
appears to be accelerated by heating the sample. 
While heating characterization described in Fig. 13 demonstrates that liposomes release encapsulated 
materials above a temperature of approximately 41 degrees, consistent with the lipid phase transition 
temperature of DPPC, the counting of liposomes in DI water as shown in Fig. 12c indicates that even 
upon heating the sample near boiling point (99 degrees C), the liposome population is not significantly 
decreased upon cooling and counting in the flow cytometer. This phenomenon can likely be explained by 
the self-repair properties of the lipids. Above the transition temperature, the kinetic energy of these 
molecules is enough to overcome the hydrophobic interactions which stabilize the bilayer structure, thus 
explaining the release of encapsulated ions. Flow cytometry analysis, however, is performed after the 
sample has been cooled again. The data in Fig. 12c is explained by the presence or absence of detergent – 
without Triton X, DPPC lipids are free to re-stabilize their ordered bilayer structures, while reformation 
of liposomes is inhibited by Triton X, which favours the formation of micelles and may sequester or 
destabilize DPPC lipids. 
In the quantification of human T lymphocytes by lysate impedance spectroscopy [109], the 
introduction of DI water is used to trigger lysis of cells and release of contents for interrogation. In this 
measurement, liposomes are more stable in DI water, likely as a result of the absence of membrane 
proteins, particularly aquaporins, which would allow for the diffusion of water molecules into the cell 
driven by the osmostic gradient. 
DI water is therefore not a suitable technique for triggering liposome permeabilization. Furthermore, 
chemical-based permeabilization is not preferred for this platform because the introduction of a reagent 
by flow necessarily results in the displacement of an equal volume of fluid from the microfluidic chamber 
and thus may result in the loss of lipids or ions and complication of the impedance measurement. Heating 
is therefore an ideal technique for stimulating the release of encapsulated ions from liposomes in the 
fluidic chamber as it allows for interrogation of the chamber without displacing its contents. 
Liposomes were initially prepared containing 1X PBS, however, 10X PBS was later employed as a 
means of amplifying the signal produced by liposome permeabilization and is used in all the data 
presented here. The lower limit of detection determined by the data in Fig. 14 shows the same signal as 
the deionized water we obtained for our experiments. It is evident that the DI water that was available to 
us did contain some small amount of ionic contamination and we anticipate that a higher sensitivity 
would be possible if DI water containing fewer ions were available. We believe that this was the case for 
the similar measurements performed with human T lymphocytes in [109] where a lower limit of detection 
is demonstrated. 
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We have demonstrated that the sensing device used in these measurements can be modeled with a 
simple circuit consisting of a capacitor, Cdi, in parallel with parasitic impedance Zpara and the series 
combination of solution resistance Rsol and interfacial impedance Zdl. From this model, the value Rsol is 
used to determine the bulk solution conductance, Gsol, which is related to the solution conductivity σ by 
the equation: 
 
    G = σmA/L (2) 
 
Where A is the solution cross-sectional areas between electrodes, L is the spacing between electrodes, and 
m is the number of electrodes [109]. For our device, the value of mA/L is 133.7 cm and this value can be 
used to determine a measured conductivity change of 0.12 GΩ-1 cm-1 (liposomes per μl)-1. This differs by 
one order of magnitude from our predicted conductivity change of 4.27 GΩ-1 cm-1 (liposomes per μl)-1, 
but can be attributed to the behaviour of ions in bulk as described by Chen, et al. [109]. 
During real-time monitoring of liposome permeabilization, two methods for quantification are 
demonstrated (Fig. 15): normalized impedance after 200 seconds and max –dZ/dt. It is still to be 
determined which method is a more consistent and sensitive method for detection. An improved 
technique which minimizes the fluctuation of device temperature during heating and heats the device 
more slowly may result in a lower baseline in the time derivative and thus allow for a lower limit of 
detection. This technique is to be optimized in future studies. 
Additionally, the liposomes described in this report exhibited significant variation in diameter. We 
anticipate that the decrease in impedance magnitude and –dZ/dt would correlate better if liposome size 
was uniform. Several microfluidic techniques which produce highly uniform liposome particles have been 
described [147], [148]. These formation methods can be pursued in future work for a more accurate 
liposome-based measurement. 
The accuracy and sensitivity of this device may also be improved by employing larger liposomes. We 
found that the lower limit of detection was approximately 1,000 liposomes/μl in our current 
measurements (average liposome diameter = 3.7 μm). Because the impedance change detected depends 
on the total volume of 10X PBS released from all liposomes on the device, larger liposomes would enable 
the sensing of fewer total particles. Furthermore, because the volume of a sphere scales with the radius 
cubed, a liposome with twice the radius of those used in our measurements would have eight times the 
volume. In other words, only one eighth of the number of liposomes per microliter would be needed to 
produce the same impedance change and fewer liposomes per microliter could be detected. As an 
example, a 10 μm diameter liposome has 19.7 times the volume of a 3.7 μm diameter liposome. We 
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would expect, therefore, to be able to detect approximately 50 liposomes/μl if 10 μm liposomes were 
used. 
Finally, the qualitative sensing of viruses based on impedance change that we demonstrated is only a 
proof-of-concept. The time of incubation with virus sample was prolonged in our current study to ensure 
ample time for virus immobilization. We believe, however, that efficient and rapid capture of viruses can 
be achieved with optimized device geometry, antibody immobilization methods, and improved protocols 
for virus capture. We are now pursuing the quantitative detection of viruses after high-efficiency 
immunocapture from whole blood or plasma from HIV-positive individuals. 
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Figures 
 
 
Fig. 12 Liposomes in various conditions were counted by flow cytometry to characterize stability. (a) 
Liposome count was measured over several hours in DI water, sugar solution, 1X PBS, and 10X PBS. 
The measurement was repeated for each condition for a total of three samples. Each repeat was fitted with 
a linear best fit. The average of the three fits is shown. (inset) Bar chart of slopes determined from 
averaged fits of three repeats of each condition. (b) Liposomes with and without protein A were 
suspended in DI water and 1% Triton X. Counting over time shows that detergent accelerates liposome 
depletion. (c) Similarly, liposomes were suspended in DI water and 1% Triton X, heated to various 
temperatures and counted with a flow cytometer after cooling to room temperature. This data suggests 
that heating accelerates the effects of detergent but does not compromise the overall structure of 
liposomes in DI, although additional data presented in this paper indicates that heating above ~41 degrees 
C promotes the release of liposome contents. Fluorescence microscopy images of samples at room 
temperature and after cooling from 90 degrees confirm flow cytometry measurements by demonstrating 
that liposome particles are still present after extreme heating. 
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Fig. 13 Liposomes encapsulating calcein were prepared, re-suspended in various media and analyzed with 
a melting curve program in a realtime PCR instrument. The sample temperature was increased from 25 
degrees C to 95 degrees C over 30 minutes and at 520 nm emission was monitored throughout. (a) Raw 
fluorescence intensity and (b) the rate of change dI/dT versus temperature show that a dramatic increase 
in fluorescence intensity occurs at approximately 41 degrees, indicating the release of calcein from within 
liposomes. This agrees with the lipid transition temperature cited by the product literature. 
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Fig. 14 (a-b) Ion-release impedance spectroscopy measurements from several heat-permeabilized 
liposome samples at concentrations ranging from 129.7 μl-1 to 50,131.5 μl-1 and (c) impedance measured 
at 2.6 kHz versus liposome concentration with fits to measurements above the limit of detection, 
approximately 1000 μl-1. (d) Simplified circuit model of electrodes in solution which is fitted to 
experimental data, accounting for the dielectric capacitance Cdi, solution resistance Rsol, series resistance 
Rser, parasitic impedance Zpara, and interfacial impedance Zdl. (e-f) Sample fits of the simplified circuit 
model to measured data for high and low concentrations. (g) Bulk conductance calculated from values for 
Rsol extracted from fitting the experimental data are plotted versus liposome concentration and fitted with 
a straight line. The slope of this line represents the sensitivity of the device. 
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Fig. 15 Real-time impedance detection of ion release from liposomes by heating of interdigitated 
electrode device. (a) Sample data for liposomes at two different concentrations is shown, including the 
normalized impedance and the stage temperature for 1,237 μl-1 and 5,546 μl-1 samples. The actual device 
temperature lags behind the stage temperature by a few seconds because it is insulated by a glass 
microscope slide. (b) Shows the normalized impedance value at 200 seconds for all samples versus 
liposome concentration with linear best fit (on a semilog axis). Measurements indicated by each unique 
symbol/color combination were recorded from the same batch of liposomes. Three different batches of 
liposomes were prepared and measured in total. (c) The rate of normalized impedance decrease, –dZ/dt, is 
plotted for the same two representative samples. (d) Summarizes all measurements with the same 
symbol/color scheme and linear best fit (on a semilog axis). Only liposome concentrations above the 
lower limit of detection (10
3
 μl-1) are fitted. 
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Fig. 16 Virus sensing by liposome tagging and ion-release impedance spectroscopy. (a) Concept of 
detection: (1) Virus is immobilized by antibody binding on the surface of the microfluidic channel. (2) 
Liposomes, functionalized with protein A (PrA) which binds the Fc region of IgG, bind specifically to 
immobilized viruses and background media is replaced by DI water. (3) Device is heated to trigger the 
release of encapsulated ions. (b) Normalized impedance data measured at 2 kHz for four repeats of virus-
containing devices and controls. (c) Summary of average impedance change after 200 seconds for virus-
containing devices (mean = 49.11%, standard deviation = 18.37%, n = 4) versus control (mean = 17.34%, 
standard deviation = 7.18%, n = 4). The averages are confirmed by two-tailed t-test to be significantly 
different with 95% confidence (t = 3.22).  
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5. Conclusion 
We have shown the sensing of viruses by tagging with functionalized ion-encapsulating liposomes 
and detection with ion-release impedance spectroscopy. This approach to biosensing seeks to address 
fundamental barriers which render current state-of-the-art diagnostic instrumentation inaccessible in many 
remote and resource-limited parts of the world. We address this primarily through the integration of an 
entirely electrically-based sensing technology with simple components. This antigen-recognition based 
biosensor assay also contains an inherent a high degree of flexibility that could be accomplished by 
simply changing the antibody used. 
This ion-release impedance sensor is an ongoing project and next steps will include strides toward a 
fully-integrated whole blood analysis platform for quantitative detection of HIV plasma viral load. 
Specifically, these steps include: 
 Characterization of immunoaffinity capture of viruses from whole blood in a microfluidic 
device. The device will be functionalized with anti-gp120 IgG and HIV-negative blood 
specimens will be spiked with viruses at known concentrations. The samples will be injected 
into the microfluidic device to perform the capture. PCR analysis will indicate the levels of virus 
in the blood that were not captured. Captured viruses will also be eluted from the fluidic 
chamber and quantified by PCR, these measurements will be used to calculate capture 
efficiency. Factors including device geometry and antibody immobilization method will be 
optimized to achieve consistent high-efficiency capture. 
 Liposome production methods will be explored to achieve consistent diameter for a more 
accurate testing method. Larger liposomes will also be explored and non-specific binding versus 
liposome size will be characterized to determine the largest allowed liposome size for this assay. 
The goal will be to improve the lower limit of detection two orders of magnitude. 
 Viruses captured from whole blood will be quantified based on the liposome ion release 
impedance spectroscopy method. Following capture, antibody-functionalized liposomes will be 
used to tag captured viruses, the device will then be heated and measured to quantify tags, which 
will indicate the number of captured viruses. 
 The fully-integrated device will be testing with clinical specimens from the Carle Foundation 
Hospital. 
Ultimately, the successful completion of this plasma viral load biosensor assay will pave the way for wide 
application of this ELISA-inspired technique to biomolecule, pathogen and toxin sensing at the point-of-
care. 
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Appendix A: Impedance sensor fabrication protocol 
Double resist metal lift-off recipe 
 
1. Piranha clean (Sulfuric Acid:Hydrogen Peroxide::1:1), 15 minutes; rinse 10 minutes; nitrogen dry. 
2. Dehydration bake @ 110 C, 5 minutes minimum; 5 minutes cool-off. 
3. Spin LOR 3A (put on enough LOR 3A to cover entire wafer before spinning; this helps chip yield 
greatly) 
a. 0 to 500 rpm in 1 s (acceleration setting) 
b. hold at 500 rpm for 2 s 
c. 500 to 3000 rpm in 2 s (acceleration setting) 
d. hold at 3000 rpm for 35 s 
4. Soft bake:  5 min. @ 183 C (directly on hotplate, not with metal holders); 5 minutes cool off 
5. Spin S1805 (put on enough S1805 to cover entire wafer, not just 4 mL) 
a. 0 to 500 rpm in 1 s (acceleration setting) 
b. hold at 500 rpm for 5 s 
c. 500 to 4000 rpm in 3 s (acceleration setting) 
d. hold at 4000 rpm for 40 s 
6. Soft bake, 90 s @ 110 C; 5 minutes cool off (important before exposure to prevent wafer from 
sticking to mask) 
7. Exposure energy: 28 mJ/cm2: 
a. 3.7 s exposure time with MNTL’s Quintel (currently 7.5 mW/cm2  power output) 
b. 2.6 s exposure time with MNMS’ Mask Aligner (currently 21.4 mW/cm2 power output) 
8. Post Exposure Bake: 60 s @ 110 C (wafer directly on hotplate) 
9. Develop in CD-26 for 18 s 
a. CD-26 underneath developer hood, on right 
b. Simply let wafer sit in developer (no agitation, swirling, etc.; this can cause features to break 
off of wafer) 
10. Rinse in DI water for 2 minutes in a dish with DI water gently flowing into it or simply swirling the 
wafer gently in a static dish of DI  water 
11. Examine wafer under microscope. 
12. Perform 20 s oxygen plasma on wafer(s) before placing in CHA for metal deposition 
13. Evaporation: 250 Angstroms of titanium + 750 Angstroms of gold per wafer 
14. Metal lift-off (do this in the biolab) 
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a. Place wafers in Remover PG at 70 C for 1 hour+ 
b. Dump liquid into non-halogenated solvent waste container 
c. Wipe gently with a cleanroom wipe to remove any stubborn metal 
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Appendix B: Data acquisition scripts 
Impedance spectroscopy measurements 
clear all; 
close all; 
 
strResponse = input('Filename to save data?\n', 's'); 
 
tic; 
 
%GPIB address 
address = 20; 
 
g = instrfind('Type', 'gpib', 'BoardIndex', 0, 'PrimaryAddress', address, 'Tag', ''); 
if isempty(g) 
    g = gpib('NI', 0, address); 
else 
    fclose(g); 
    g = g(1); 
end 
fopen(g); 
 
fprintf(g,'FUNC:IMP ZTD') 
fprintf(g,'VOLT 250 MV') 
 
%4284A 
%FREQ Array gives all frequency test values 
frequencies = load('frequencies.mat','frequency'); 
scanthis = frequencies.frequency; 
 
S = zeros(24,4); 
 
%scan times: 
 
fprintf('FREQUENCY,MAGNITUDE,PHASE (1)') 
fprintf('\n') 
 
for i = 1:24 
    %Set FREQ 
    FREQ = ['FREQ ' sprintf('%g', scanthis(i)) 'HZ']; 
    fprintf(g,FREQ); 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
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    DISPLAY = [int2str(scanthis(i)) ',' int2str(D(1)) ',' int2str(D(2))]; 
    fprintf(DISPLAY) 
    fprintf('\n') 
    S(i,:) = [D Q]; 
end 
 
fprintf('FREQUENCY,MAGNITUDE,PHASE (2)') 
fprintf('\n') 
for i = 1:24 
    %Set FREQ 
    FREQ = ['FREQ ' sprintf('%g', scanthis(i)) 'HZ']; 
    fprintf(g,FREQ); 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    DISPLAY = [int2str(scanthis(i)) ',' int2str(D(1)) ',' int2str(D(2))]; 
    fprintf(DISPLAY) 
    fprintf('\n') 
    S2(i,:) = [D Q]; 
end 
 
fprintf('FREQUENCY,MAGNITUDE,PHASE (3)') 
fprintf('\n') 
for i = 1:24 
    %Set FREQ 
    FREQ = ['FREQ ' sprintf('%g', scanthis(i)) 'HZ']; 
    fprintf(g,FREQ); 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    DISPLAY = [int2str(scanthis(i)) ',' int2str(D(1)) ',' int2str(D(2))]; 
    fprintf(DISPLAY) 
    fprintf('\n') 
    S3(i,:) = [D Q]; 
end 
 
fclose(g); 
delete(g); 
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save(strResponse,'S','S2','S3'); 
 
toc 
 
load('di_ref.mat'); 
 
hold on; 
p = semilogx(di_ref(:,4),di_ref(:,1),'--'); 
p = semilogx(S(:,4),S(:,1)); 
p = semilogx(S2(:,4),S2(:,1)); 
p = semilogx(S3(:,4),S3(:,1)); 
set(gca,'XScale','log'); 
hold off; 
 
figure; 
 
hold on; 
p = semilogx(di_ref(:,4),di_ref(:,2),'--'); 
p = semilogx(S(:,4),S(:,2)); 
p = semilogx(S2(:,4),S2(:,2)); 
p = semilogx(S3(:,4),S3(:,2)); 
set(gca,'XScale','log'); 
hold off; 
 
pause(10); 
 
close all; 
 
Frequencies.mat 
This file lists measurement frequencies and is called in the above script. 
100 
150 
225 
337.500000000000 
506.250000000000 
759.375000000000 
1139.06250000000 
1708.59375000000 
2562.89062500000 
3844.33593800000 
5766.50390600000 
8649.75585900000 
12974.6337900000 
19461.9506800000 
29192.9260300000 
43789.3890400000 
65684.0835600000 
98526.1253400000 
 60 
 
147789.188000000 
221683.782000000 
332525.673000000 
498788.509500000 
748182.764300000 
1000000 
Real-time impedance measurements 
clear all; 
close all; 
 
strResponse3 = input('Filename to starting sweep data?\n', 's'); 
strResponse = input('Filename to save time data?\n', 's'); 
strResponse2 = input('Filename to final sweep data?\n', 's'); 
 
%GPIB address 
address = 20; 
 
g = instrfind('Type', 'gpib', 'BoardIndex', 0, 'PrimaryAddress', address, 'Tag', ''); 
if isempty(g) 
    g = gpib('NI', 0, address); 
else 
    fclose(g); 
    g = g(1) 
end 
fopen(g); 
 
fprintf(g,'FUNC:IMP ZTD') 
fprintf(g,'VOLT 250 MV') 
 
%4284A 
%FREQ Array gives all frequency test values 
frequencies = load('frequencies.mat','frequency'); 
scanthis = frequencies.frequency; 
 
S = zeros(24,4); 
 
%scan times: 
 
for i = 1:24 
    %Set FREQ 
    FREQ = ['FREQ ' sprintf('%g', scanthis(i)) 'HZ']; 
    fprintf(FREQ) 
    fprintf('\n') 
    fprintf(g,FREQ); 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
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    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    B(i,:) = [D Q]; 
end 
 
save(strResponse3,'B'); 
 
semilogx(B(:,4),B(:,1)); 
 
figure; 
 
semilogx(B(:,4),B(:,2)); 
 
fprintf(g,'FUNC:IMP ZTD') 
fprintf(g,'VOLT 250 MV') 
 
 
disp('Press enter to start time sweep'); 
pause; 
disp('TIME SWEEP IN PROGRESS'); 
 
starttime = clock; 
 
C = 0; 
i = 1; 
figure('Position',[0 0 1024 768]); 
 
while C<5400 
    %Set FREQ 2kHz 
    FREQ = ['FREQ 2000 HZ']; 
    fprintf(g,FREQ) 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    nowtime = clock; 
    C = 60*60*(nowtime(4)-starttime(4))+60*(nowtime(5)-starttime(5))+nowtime(6)-starttime(6); 
    A = nowtime; 
    F(i,:) = [D Q C A]; 
    %Set FREQ 10kHz 
    FREQ = ['FREQ 10000 HZ']; 
    fprintf(g,FREQ) 
    pause(0.2) 
    %FETCH 
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    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    nowtime = clock; 
    C = 60*60*(nowtime(4)-starttime(4))+60*(nowtime(5)-starttime(5))+nowtime(6)-starttime(6); 
    A = nowtime; 
    G(i,:) = [D Q C A]; 
    %Set FREQ 100kHz 
%     FREQ = ['FREQ 100000 HZ']; 
%     fprintf(g,FREQ) 
%     pause(0.2) 
%     %FETCH 
%     fprintf(g,'FETCH?') 
%     f = fscanf(g); 
%     D = sscanf(f,'%f,%f,%f',[1,3]); 
%     %FREQ? 
%     fprintf(g,'FREQ?') 
%     f = fscanf(g); 
%     Q = sscanf(f,'%f'); 
%     nowtime = clock; 
%     C = 60*60*(nowtime(4)-starttime(4))+60*(nowtime(5)-starttime(5))+nowtime(6)-starttime(6); 
%     A = nowtime; 
%     H(i,:) = [D Q C A]; 
    subplot(2,1,1); 
    plot(F(:,5),F(:,1),G(:,5),G(:,1)); 
    legend('2 kHz','10 kHz'); 
    ylabel('Impedance (\Omega)'); 
    xlabel('Time (s)'); 
    title('Impedance Magnitude in Real Time'); 
    if i>1 
        diffF = diff(F(:,1))./diff(F(:,5)); 
        diffG = diff(G(:,1))./diff(G(:,5)); 
        subplot(2,1,2); 
        plot(F(1:i-1,5),diffF,G(1:i-1,5),diffG); 
        legend('2 kHz','10 kHz'); 
        ylabel('d\Omega/dt'); 
        xlabel('Time (s)'); 
        title('Impedance Magnitude in Real Time'); 
    end 
    i = i+1; 
    save(strResponse, 'F', 'G'); 
end 
 
fprintf(g,'FUNC:IMP ZTD') 
fprintf(g,'VOLT 250 MV') 
 
%4284A 
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%FREQ Array gives all frequency test values 
frequencies = load('frequencies.mat','frequency'); 
scanthis = frequencies.frequency; 
 
S = zeros(24,4); 
 
%scan times: 
 
for i = 1:24 
    %Set FREQ 
    FREQ = ['FREQ ' sprintf('%g', scanthis(i)) 'HZ']; 
    fprintf(FREQ) 
    fprintf('\n') 
    fprintf(g,FREQ); 
    pause(0.2) 
    %FETCH 
    fprintf(g,'FETCH?') 
    f = fscanf(g); 
    D = sscanf(f,'%f,%f,%f',[1,3]); 
    %FREQ? 
    fprintf(g,'FREQ?') 
    f = fscanf(g); 
    Q = sscanf(f,'%f'); 
    S(i,:) = [D Q]; 
end 
 
save(strResponse2,'S'); 
 
semilogx(S(:,4),S(:,1)); 
 
figure; 
 
semilogx(S(:,4),S(:,2)); 
 
fclose(g); 
delete(g); 
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Appendix C: Fitting protocol 
Primary fitting script: fit_PCR.m 
% Fit a certain function to measured impedance data 
% Can choose to fit to mag-angle or real-imag 
% Rafael Gomez 10/23/00 edited by Gregory Damhorst 3/22/13 
clear all; 
close all; 
clc; 
 
% Model 
model = 'jacobs_PCR'; 
 
% Fit to mag-angle or real-imag? 
% fmag = 1 --> mag-angle; fmag = 0 --> real_imag 
fitmag = 1; 
 
% First guess for parameters 
% p0 = input('first guess of parameters:'); %jacobs 
p0 = [1 10 1 1]; 
 
% Fix any parameters? 
% Indexes of parameters to hold fixed 
fixindex = []; 
% Values of fixed parameters, corresponding to the indexes in fixindex 
fixvalues = []; 
 
% Plot only, no fit? 
% If plotonly==1, data and model are plotted (with p0), but no fit is done 
plotonly = 0; 
 
% Accumulate figures? 
accum = 1; 
 
% Load data 
fname = '../130215_imp_spec/130215_A2.mat'; 
savename = '../130215_imp_spec/130323_fit_A2.mat'; 
load(fname); 
%data is in S 
 
% Column 1 is frequency 
freq = 2*pi*S(:, 4); 
data(:,1) = freq; %just in case 
% Column 2 is impedance magnitude 
data(:,2) = S(:,1); 
% Column 3 is impedance angle 
data(:,3) = S(:, 2)*pi/180; 
% Fourth column is Real(Z) 
data(:, 4) = data(:, 2).*cos(data(:, 3)); 
% Fifth column is Imag(Z) 
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data(:, 5) = data(:, 2).*sin(data(:, 3)); 
 
% Frequency range to fit 
rng = 1:24; 
 
% Select kind of data to fit 
z = zeros(length(rng), 2); 
if fitmag 
   % Mag-angle 
 z(:, 1) = log(data(rng, 2)); 
 z(:, 2) = data(rng, 3); 
else 
   % Real-imag 
   z(:, 1) = log(data(rng, 4)); 
   z(:, 2) = log(data(rng, 5)); 
end; 
 
% Display settings 
disp(['File: ' fname]); 
disp(['Model: ' upper(model)]); 
if fitmag 
    disp('Fitting to MAGNITUDE-ANGLE'); 
else 
    disp('Fitting to REAL-IMAGINARY'); 
end 
 
% These two lines eliminate the need for jacob_pcr_info.m 
parnames = {'Rsol', 'Cdi', 'n', 'B'}; 
parunits = {'kOhm', 'pF', 'x1e-2', 'x1e-10'}; 
 
numpars = length(parnames); 
disp(['Freq. range: ' num2str(data(rng(1), 1), '%5.4e') ' Hz to '  num2str(data(rng(end), 1), '%5.4e') ' Hz']); 
disp('First guess of parameters:'); 
[snames, sunits, svalues] = fmt_params(parnames, parunits, p0); 
disp(snames); 
disp(sunits); 
disp(svalues); 
 
% Upper bounds 
pupp = inf*ones(size(p0)); 
% Lower bounds 
plow = 1e-10*ones(size(p0)); 
 
p = p0; 
if ~plotonly 
   tolfun = 1e-10; 
 for ii = 1:2 
      opt = optimset('TolX', 1e-12, 'MaxFunEvals', 1000000, 'TolFun', tolfun, ... 
         'MaxIter', 1000000, 'LargeScale', 'on', 'Display', 'on'); 
  [p, residue] = lsqcurvefit(model, p0, freq(rng), z, plow, pupp, opt, fitmag, fixindex, 
fixvalues); 
 66 
 
      p0 = p; 
  tolfun = tolfun/1000; 
   end; 
end; 
 
if ~plotonly 
    % Display results from fit 
    disp('  '); 
    disp('Parameters from fit:'); 
    [snames, sunits, svalues] = fmt_params(parnames, parunits, p0); 
    disp(snames); 
    disp(sunits); 
    disp(svalues); 
    disp(' '); 
    disp(['Residue per point from lsqcurvefit: ' num2str(residue/length(rng), '%5.4e') ' (' int2str(length(rng)) 
' points)']); 
end 
 
%w = logspace(2.6, 7, 100)'; 
w = freq; 
zfit = zeros(length(w), 4); 
if fitmag 
 zfit(:, 1:2) = feval(model, p, w, fitmag, fixindex, fixvalues); 
 zfit(:, 1) = exp(zfit(:, 1)); 
 zfit(:, 3) = zfit(:, 1).*cos(zfit(:, 2)); 
 zfit(:, 4) = zfit(:, 1).*sin(zfit(:, 2)); 
else 
   zfit(:, 3:4) = exp(feval(model, p, w, fitmag, fixindex, fixvalues)); 
   zcomp = zfit(:, 3) + i*zfit(:, 4); 
   zfit(:, 1) = abs(zcomp); 
   zfit(:, 2) = angle(zcomp); 
end; 
 
if ~plotonly 
    % Calculate residues from real-imag 
    res_ri = sum((log(data(:, 4)) - log(zfit(:, 3))).^2) + sum((log(data(:, 5)) - log(zfit(:, 4))).^2); 
    % Calculate resides from mag-angle 
    res_ma = sum((log(data(:, 2)) - log(zfit(:, 1))).^2) + sum((data(:, 3) - zfit(:, 2)).^2); 
    disp(['Residue per point (real-imag): ' num2str(res_ri/length(rng), '%5.4e') ' (' int2str(length(rng)) ' 
points)']); 
    disp(['Residue per point (mag-angle): ' num2str(res_ma/length(rng), '%5.4e') ' (' int2str(length(rng)) ' 
points)']); 
    disp(''); 
    disp(['Total residue per point (r-i + m-a): ' num2str((res_ri + res_ma)/length(rng), '%5.4e') ' (' 
int2str(length(rng)) ' points)']); 
end 
     
tit = ['Fit to ', fname, '  with ', model]; 
if 1 
   if accum 
      fh = figure; 
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   else 
      fh = figure(1); 
   end; 
%   set(fh, 'position', [200 430 750 500]); 
%   set(fh, 'PaperPosition', [0.83 3.28 6.84 4.44]); 
   subplot(2, 1, 1); 
 ph = []; 
   ph = [ph loglog(data(:, 1)/(2*pi), abs(data(:, 4)), 'k+', w/(2*pi), abs(zfit(:, 3)))]; 
   set(ph, 'MarkerSize', 10); 
   th = title(tit); 
   set(th, 'Interpreter', 'none'); 
   xlabel('Frequency [Hz]'); 
   ylabel('Real(Z) [{\Omega}]'); 
   %legend('Measured', 'Fitted model'); 
    
   subplot(2, 1, 2); 
   ph = [ph loglog(data(:, 1)/(2*pi), abs(data(:, 5)), 'k+', w/(2*pi), abs(zfit(:, 4)))]; 
   set(ph, 'MarkerSize', 10); 
   xlabel('Frequency [Hz]'); 
   ylabel('Imag(Z) [{\Omega}]'); 
%   plformat(fh, ph, 14); 
   legend( 'Measured', 'Fitted model'); 
end 
 
if 1 
   if accum 
      fh = figure; 
   else 
      fh = figure(2); 
   end; 
%   set(fh, 'position', [250 380 750 500]); 
%   set(fh, 'PaperPosition', [0.83 3.28 6.84 4.44]); 
 ph = []; 
   subplot(2, 1, 1); 
   ph = [ph loglog(data(:, 1)/(2*pi), data(:, 2), 'k+', w/(2*pi), zfit(:, 1))]; 
   set(ph, 'MarkerSize', 10); 
   th = title(tit); 
   set(th, 'Interpreter', 'none'); 
%    axis([20 1e6 0 1E9]); 
 xlabel('Frequency [Hz]'); 
   ylabel('Impedance Magnitude [{\Omega}]'); 
    
   subplot(2, 1, 2); 
   ph = [ph semilogx(data(:, 1)/(2*pi), data(:, 3)*180/pi, 'k+', w/(2*pi), zfit(:, 2)*180/pi)]; 
   set(ph, 'MarkerSize', 10); 
%    axis([20 1e6 -90 0]); 
   xlabel('Frequency [Hz]'); 
   ylabel('Angle [Deg]'); 
%   plformat(fh, ph, 14); 
   legend( 'Measured', 'Fitted model'); 
end 
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f = w/(2*pi); 
save(savename,'f','zfit','snames','sunits','svalues'); 
 
Function: fmt_params 
function [snames, sunits, svalues] = fmt_params(parnames, parunits, par); 
% FMT_PARAMS Returns strings with the formatted parameters, for printing 
% 
% [snames, sunits, svalues] = fmt_params(parnames, parunits, par) 
% 
%    parnames = Cell array of strings with names of parameters 
%    parunits = Cell array of strings with units of parameters 
%    par = Vector with values of parameters 
% 
%    snames = String with formatted names of paramaters 
%    spares = String with formatted names of paramaters 
%    svalues = String with formatted values of paramaters 
% 
% R. Gomez 8/3/02 
 
% Build arrays with names and units fo parameetrs 
numpars = length(parnames); 
snames = '    '; 
sunits = '    '; 
svalues = 'p = '; 
dummy = '                                           '; 
for ii = 1:numpars 
    vv = num2str(par(ii), '%5.4e'); 
    ln = length(parnames{ii}); 
    lu = length(parunits{ii}); 
    lv = length(vv); 
    lmax = max([ln lu lv]) + 2; 
    tmp = dummy(1:(lmax-ln)); 
    snames = [snames parnames{ii} tmp]; 
    tmp = dummy(1:(lmax-lu)); 
    sunits = [sunits parunits{ii} tmp]; 
    tmp = dummy(1:(lmax-lv)); 
    svalues = [svalues vv tmp]; 
end 
 
 
